Schaffhausen, Switzerland

Sandro Delmenico

This inventor holds 2 USPTO granted patents. Top assignee: Cilag International Gmbh. Active years: 1998-2003.


% Patents Active = 100.0

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 27(Granted Patents)


Company Filing History:


Years Active: 1998-2003

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Sandro Delmenico: Innovator in Liposomal Formulations

Introduction

Sandro Delmenico is a notable inventor based in Schaffhausen, Switzerland. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of liposome-based products. With a total of 2 patents, his work focuses on enhancing the delivery of therapeutic agents through innovative formulations.

Latest Patents

Delmenico's latest patents include a formulation for erythropoietin liposomal dispersion and a liposome-based topical vitamin D formulation. The latter is particularly noteworthy as it offers good skin penetration of the effective substance, calcitriol. This formulation is well suited for the treatment of psoriasis, showcasing Delmenico's commitment to addressing important medical needs.

Career Highlights

Sandro Delmenico is associated with Cilag International GmbH, a company known for its advancements in pharmaceutical products. His work at Cilag has allowed him to focus on innovative solutions that improve patient outcomes through effective drug delivery systems.

Collaborations

Delmenico has collaborated with esteemed colleagues such as Rainer Naeff and Rene Spycher. These partnerships have contributed to the development of his innovative formulations and have enhanced the research capabilities within his field.

Conclusion

Sandro Delmenico's contributions to liposomal formulations demonstrate his expertise and dedication to improving therapeutic delivery systems. His innovative work continues to impact the pharmaceutical industry positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…